267. 高IgD症候群 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 11 / 薬物数 : 6 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 44

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
ACZ885   
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
ACZ885, 150mg/1.0ml   
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Canakinumab   
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01303380   Spain;
ITF2357   
   Radboud University
      2006   Phase 2   NCT00442182   Netherlands;
Ilaris   
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan;